KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Assets (2016 - 2025)

Charles River Laboratories International has reported Assets over the past 17 years, most recently at $7.1 billion for Q4 2025.

  • For Q4 2025, Assets fell 5.22% year-over-year to $7.1 billion; the TTM value through Dec 2025 reached $7.1 billion, down 5.22%, while the annual FY2025 figure was $7.1 billion, 5.22% down from the prior year.
  • Assets for Q4 2025 was $7.1 billion at Charles River Laboratories International, down from $7.5 billion in the prior quarter.
  • Over five years, Assets peaked at $8.2 billion in Q4 2023 and troughed at $5.8 billion in Q1 2021.
  • A 5-year average of $7.4 billion and a median of $7.5 billion in 2022 define the central range for Assets.
  • Biggest five-year swings in Assets: grew 28.23% in 2021 and later fell 8.13% in 2024.
  • Year by year, Assets stood at $7.0 billion in 2021, then rose by 8.24% to $7.6 billion in 2022, then grew by 7.79% to $8.2 billion in 2023, then dropped by 8.13% to $7.5 billion in 2024, then decreased by 5.22% to $7.1 billion in 2025.
  • Business Quant data shows Assets for CRL at $7.1 billion in Q4 2025, $7.5 billion in Q3 2025, and $7.6 billion in Q2 2025.